TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10770199

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Dichloroacetate
Number of subjects: 21

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: L-[3-13C1]sodium lactate and D-[6,6-D2]glucose infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 21
Study: 9354211

Group type: EXPERIMENTAL
Intervention: 30 mg pentazocine i.v.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 50 mg tilidine i.v.
Number of subjects: 20
Study: 8409145

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric evaluation and outpatient care management program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3535006

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 28135225

Group type: EXPERIMENTAL
Intervention: Laddermill (LM) exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Treadmill (TM) exercise
Number of subjects: 20
Study: 28005113

Group type: EXPERIMENTAL
Intervention: Tablet questionnaires
Number of subjects: 483

Group type: COMPARATOR
Intervention: Paper questionnaires
Number of subjects: 483
Study: 25858478

Group type: EXPERIMENTAL
Intervention: Colestyramine 4 g twice daily
Number of subjects: 26
Study: 23565660

Group type: EXPERIMENTAL
Intervention: Oral combined vitamins for 1 year
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group with normal vitamin levels
Number of subjects: 60
Study: 21639806

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 4560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4560
Study: 19210023

Group type: EXPERIMENTAL
Intervention: Primed (subliminal prime to activate common cold schema)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no subliminal prime)
Number of subjects: 0
Study: 17106408

Group type: EXPERIMENTAL
Intervention: Proview pressure phosphene tonometry (PPPT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Goldmann tonometry (GT)
Number of subjects: 104
Study: 15231980

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg on day 1 and 5 mg/kg on days 2-5)
Number of subjects: 477

Group type: COMPARATOR
Intervention: Erythromycin estolate (40 mg/kg/day in 3 divided doses for 10 days)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 477

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 477
Study: 11764322

Group type: EXPERIMENTAL
Intervention: Natural frequency analysis (NF)
Number of subjects: 698
Study: 9226734

Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amisulpride 100 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7867225

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with fish oils
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (age-matched subjects)
Number of subjects: 16
Study: 2517679

Group type: EXPERIMENTAL
Intervention: Glucose (group G)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Glucose + Intralipid 10% (group GL)
Number of subjects: 65
Study: 782956

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 17-butyrate (HC 17-B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 21-acetate (HA)
Number of subjects: 0
Study: 31202455

Group type: EXPERIMENTAL
Intervention: Combined acoustic radiation force impulse (ARFI) imaging and conventional ultrasound (US)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Conventional ultrasound (US) index (renal length, renal parenchyma thickness and interlobular arterial RI)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Shear wave velocity (SWV)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Conventional US index
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (39 healthy volunteers)
Number of subjects: 146
Study: 29033560

Group type: EXPERIMENTAL
Intervention: Proactive palliative care in monthly meetings with a specialized palliative care team (SPCT)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 228
Study: 26149129

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 2.5 mg/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Pitavastatin 2 mg/day
Number of subjects: 46
Study: 24452168

Group type: EXPERIMENTAL
Intervention: PCR testing with concurrent antistaphylococcal antibiotics
Number of subjects: 0
Study: 22952075

Group type: EXPERIMENTAL
Intervention: Oral tropisetron at 5 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral tropisetron at 10 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oral tropisetron at 20 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20937929

Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogens (CEE)
Number of subjects: 27747

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (CEE plus medroxyprogesterone acetate 2.5 mg/d)
Number of subjects: 27747

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27747
Study: 18249107

Group type: EXPERIMENTAL
Intervention: Buteyko technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (breathing and relaxation techniques)
Number of subjects: 0
Study: 15860686

Group type: EXPERIMENTAL
Intervention: Military anti-shock trouser pants inflation
Number of subjects: 44
Study: 14660821

Group type: EXPERIMENTAL
Intervention: Bolus hydration
Number of subjects: 63

Group type: COMPARATOR
Intervention: Overnight hydration
Number of subjects: 63
Study: 10805061

Group type: EXPERIMENTAL
Intervention: Flosequinan 50 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Flosequinan 100 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Flosequinan 150 mg
Number of subjects: 18
Study: 9347069

Group type: EXPERIMENTAL
Intervention: Exhaled carbon monoxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urinary cotinine/creatinine ratio
Number of subjects: 0
Study: 7685176

Group type: EXPERIMENTAL
Intervention: 25 mg captopril twice a day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 3320747

Group type: EXPERIMENTAL
Intervention: Noninvasive approach
Number of subjects: 57
Study: 28222446

Group type: EXPERIMENTAL
Intervention: Immediate catheter removal (Group A)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Delayed catheter removal (Group B)
Number of subjects: 295
Study: 27626622

Group type: EXPERIMENTAL
Intervention: Sertraline, 100 mg/d for 24 weeks
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 23992559

Group type: EXPERIMENTAL
Intervention: Nitroglycerin-potentiated HUT
Number of subjects: 369
Study: 22529363

Group type: EXPERIMENTAL
Intervention: Dopamine enhancement using levodopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20695007

Group type: EXPERIMENTAL
Intervention: 4.5mg nightly naltrexone (low-dose naltrexone, LDN)
Number of subjects: 80
Study: 19029083

Group type: COMPARATOR
Intervention: 0-50 ng/mL rhVEGF(165) for 7 days in vitro
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 or 50 ng/mL rhVEGF(165) for one hour prior to implantation
Number of subjects: 0
Study: 16179956

Group type: EXPERIMENTAL
Intervention: NMR pulse sequences; treatment duration: 9 days
Number of subjects: 0
Study: 12706694

Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination (3 doses of 25 microg of protein each, with 6 weeks interval and a third dose after 10 months)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Intranasal vaccination (4 weekly doses followed by a fifth dose after 5 months, each dose consisting of OMVs equivalent to 250 microg of protein)
Number of subjects: 22
Study: 10655798

Group type: EXPERIMENTAL
Intervention: 2-hour turning interval
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Core body temperature
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Skin surface temperature
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sacral skin surface temperature
Number of subjects: 26
Study: 8678499

Group type: EXPERIMENTAL
Intervention: 20 mg THP vesical irrigation
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 30 mg THP vesical irrigation
Number of subjects: 74
Study: 8479593

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2452505

Group type: EXPERIMENTAL
Intervention: Urethral dilation and TUR P
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Urethrotomy according to Otis and TUR P
Number of subjects: 317

Group type: COMPARATOR
Intervention: TUR P alone
Number of subjects: 317
Study: 29507282

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Non-remitters
Number of subjects: 75
Study: 26442992

Group type: EXPERIMENTAL
Intervention: Graphic images with text warnings on cigarette packages
Number of subjects: 2192

Group type: COMPARATOR
Intervention: Text warnings only
Number of subjects: 2192

Group type: COMPARATOR
Intervention: Current US Surgeon General's text warnings
Number of subjects: 2192
Study: 24019196

Group type: EXPERIMENTAL
Intervention: Multidisciplinary intervention (six 90-min in-person sessions including spiritual component)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group (forms only)
Number of subjects: 131
Study: 22681244

Group type: EXPERIMENTAL
Intervention: Daily dosing prophylaxis
Number of subjects: 13

Group type: COMPARATOR
Intervention: Standard prophylactic dosing regimen
Number of subjects: 13
Study: 20447161

Group type: EXPERIMENTAL
Intervention: Clinician-supported training of the Nasal Airflow Inducing Manoeuvre (NAIM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Home practice of the Nasal Airflow Inducing Manoeuvre (NAIM)
Number of subjects: 40
Study: 18227328

Group type: EXPERIMENTAL
Intervention: Percutaneous radiofrequency lumbar sympathectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lumbar sympathetic neurolysis with phenol 7%
Number of subjects: 20
Study: 16186372

Group type: EXPERIMENTAL
Intervention: Intravitreal injection (IVI) of 4 mg triamcinolone acetonide (TA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sub-Tenon's infusion (STi) of 40 mg triamcinolone acetonide (TA)
Number of subjects: 36
Study: 14578254

Group type: EXPERIMENTAL
Intervention: NCEP definition
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Impaired Glucose Tolerance (IGT)
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: Combination of IGT and NCEP definitions
Number of subjects: 1734

Group type: EXPERIMENTAL
Intervention: NCEP definition with fasting glucose >or=5.4 mmol/l
Number of subjects: 1734

Group type: COMPARATOR
Intervention: Modified WHO definition
Number of subjects: 1734
Study: 10947341

Group type: EXPERIMENTAL
Intervention: Zanamivir treatment (bid)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Zanamivir treatment (qid)
Number of subjects: 722

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Zanamivir treatment (bid and qid)
Number of subjects: 722
Study: 8777296

Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole, amoxycillin, and bismuth)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loxiglumide (LOX) administration after Hp eradication
Number of subjects: 10

Group type: COMPARATOR
Intervention: Helicobacter pylori infection
Number of subjects: 10
Study: 1806610

Group type: EXPERIMENTAL
Intervention: Cyclic estrogen‐progestin plus calcium
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Calcium (calcium carbonate with meals to attain an intake of 1,700 mg daily)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 6749443

Group type: EXPERIMENTAL
Intervention: 20 mg of methylprednisolone sodium succinate given intravenously every six hours for seven days
Number of subjects: 10

Group type: COMPARATOR
Intervention: 125 mg of methylprednisolone sodium succinate given intravenously every six hours for seven days
Number of subjects: 10
Study: 31348579

Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg at 2-week intervals
Number of subjects: 63
Study: 28363433

Group type: EXPERIMENTAL
Intervention: Heavy resistance training (HRT) 3×/week for 12 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Heavy resistance training (HRT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 26
Study: 26667312

Group type: EXPERIMENTAL
Intervention: Sad film clip
Number of subjects: 178

Group type: COMPARATOR
Intervention: Neutral film clip
Number of subjects: 178
Study: 24124061

Group type: EXPERIMENTAL
Intervention: PREMIER lifestyle intervention
Number of subjects: 501
Study: 21863237

Group type: EXPERIMENTAL
Intervention: PX-12 administered at 400 mg/m(2)/day by 72-hour infusion
Number of subjects: 14
Study: 19415555

Group type: EXPERIMENTAL
Intervention: High Intolerance of Uncertainty (IU) and High Situational Uncertainty (SU)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Low Intolerance of Uncertainty (IU) and Low Situational Uncertainty (SU)
Number of subjects: 153
Study: 17307180

Group type: EXPERIMENTAL
Intervention: Bone morphogenic protein (BMP)
Number of subjects: 0
Study: 14978184

Group type: EXPERIMENTAL
Intervention: SRL-ST
Number of subjects: 430

Group type: COMPARATOR
Intervention: SRL-CsA-ST
Number of subjects: 430
Study: 11230885

Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (IF-RT) at 26 Gy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (IF-RT) at 40 Gy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (IF-RT) at 40 Gy for patients in partial response (PR) after CHOP
Number of subjects: 140
Study: 9737645

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.025-0.4 mg/day
Number of subjects: 2700

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.4 mg/day
Number of subjects: 2700

Group type: COMPARATOR
Intervention: Cerivastatin
Number of subjects: 2700
Study: 7985630

Group type: EXPERIMENTAL
Intervention: Midluteal phase dietary intake
Number of subjects: 18
Study: 2537563

Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 253

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 253
Study: 1192347

Group type: EXPERIMENTAL
Intervention: Vincristine plus prednisone
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 6‐mercaptopurine plus prednisone
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 6‐mercaptopurine alone
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 6‐mercaptopurine plus prednisone for 4 weeks every 3 months
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 6‐mercaptopurine plus prednisone plus vincristine for 4 weeks every 3 months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Vincristine added to prednisone for reinforcement
Number of subjects: 180
Study: 30489352

Group type: EXPERIMENTAL
Intervention: Glutamine supplementation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29086484

Group type: EXPERIMENTAL
Intervention: Motivational interviewing and internet condition (MIC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nutrition psychoeducation and internet condition (NPC)
Number of subjects: 59
Study: 26343603

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.4 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 23561002

Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen (IBUg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (PLAg)
Number of subjects: 50
Study: 21525198

Group type: EXPERIMENTAL
Intervention: 2 mg riboflavin for 8 weeks
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 4 mg riboflavin for 8 weeks
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation
Number of subjects: 123
Study: 18439662

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 17062966

Group type: EXPERIMENTAL
Intervention: Aprotinin (Group-I; n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (Group-II; n=40)
Number of subjects: 80
Study: 12642183

Group type: EXPERIMENTAL
Intervention: Clumsy children
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 11203855

Group type: EXPERIMENTAL
Intervention: Fortify
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Protect‐it!
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Optiguard
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control Group (no sealing)
Number of subjects: 20
Study: 9117838

Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Topical streptokinase
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (non-streptokinase-treated wounds)
Number of subjects: 144
Study: 8478851

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block using steroid/bupivacaine
Number of subjects: 0
Study: 3529902

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training program (3 sessions per week for 8 months)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 32
Study: 30076327

Group type: EXPERIMENTAL
Intervention: Reactive gluteus medius (GM) activity during perturbed walking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GM activity of the swing leg in response to platform translation late in the gait cycle
Number of subjects: 0
Study: 27187267

Group type: EXPERIMENTAL
Intervention: Rapid outreach suicide preventive intervention (OPAC)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 133
Study: 24917198

Group type: EXPERIMENTAL
Intervention: Pregnenolone (titrated to 500 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 22532639

Group type: EXPERIMENTAL
Intervention: Continuous NSAID treatment
Number of subjects: 150

Group type: COMPARATOR
Intervention: On-demand NSAID treatment
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both treatments (continuous and on-demand)
Number of subjects: 150
Study: 20360277

Group type: EXPERIMENTAL
Intervention: Psychiatric advance directives (PADs) documenting medication preferences
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Being prescribed at least one medication requested in the psychiatric advance directive
Number of subjects: 123
Study: 18585837

Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL) therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Calcineurin-inhibitor (CNI) therapy (Control)
Number of subjects: 39
Study: 15812073

Group type: EXPERIMENTAL
Intervention: alpha‐tocopherol (400 IU/day)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study: 12934178

Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir (Idv/Rtv; 800/100 mg 2 times daily)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Saquinavir/ritonavir (Sqv/Rtv; 1000/100 mg 2 times daily)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir (Idv/Rtv)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Saquinavir/ritonavir (Sqv/Rtv)
Number of subjects: 306
Study: 10800876

Group type: EXPERIMENTAL
Intervention: 5 mg salbutamol and 500 microg ipratropium
Number of subjects: 50

Group type: COMPARATOR
Intervention: 5 mg salbutamol
Number of subjects: 50

Group type: COMPARATOR
Intervention: 500 microg ipratropium
Number of subjects: 50
Study: 8862477

Group type: EXPERIMENTAL
Intervention: High Protein (HP) diet at 1.5 x RMR with an additional 0.6 x RMR as protein
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High Carbohydrate (HC) diet at 1.5 x RMR with an additional 0.6 x RMR as carbohydrate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High Fat (HF) diet at 1.5 x RMR with an additional 0.6 x RMR as fat
Number of subjects: 6
Study: 1536666

Group type: EXPERIMENTAL
Intervention: Auranofin (AUR)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Combination of Auranofin and Methotrexate
Number of subjects: 335
Study: 6388524

Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30946860

Group type: EXPERIMENTAL
Intervention: 30 mg cortisol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27296170

Group type: EXPERIMENTAL
Intervention: Tested toothpaste containing potassium nitrate (5.00%) and zinc citrate (0.50%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what control was used)
Number of subjects: 0
Study: 26823271

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 50
Study: 24641586

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 10,000 IU weekly, titrated up to 50,000 IU weekly if necessary
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Cholecalciferol treatment
Number of subjects: 352
Study: 22564753

Group type: EXPERIMENTAL
Intervention: 100 mg of fenofibrate per each hemodialysis day for 4 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 20412423

Group type: EXPERIMENTAL
Intervention: Dapoxetine (30 mg or 60 mg as needed [PRN])
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 17671159

Group type: EXPERIMENTAL
Intervention: L‐BLP25 (peptide vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study: 16536310

Group type: EXPERIMENTAL
Intervention: Health education (1, 2, or 3+ sessions)
Number of subjects: 117

Group type: COMPARATOR
Intervention: No health education (Group 1)
Number of subjects: 117